vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $104.0M, roughly 1.3× Origin Bancorp, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 26.6%, a 8.9% gap on every dollar of revenue. Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 3.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
ADMA vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $104.0M |
| Net Profit | $49.4M | $27.7M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 26.6% |
| Revenue YoY | 18.4% | — |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $139.2M | $103.4M | ||
| Q3 25 | $134.2M | $109.8M | ||
| Q2 25 | $122.0M | $83.5M | ||
| Q1 25 | $114.8M | $94.1M | ||
| Q4 24 | $117.5M | $78.3M | ||
| Q3 24 | $119.8M | $90.8M | ||
| Q2 24 | $107.2M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | $49.4M | $29.5M | ||
| Q3 25 | $36.4M | $8.6M | ||
| Q2 25 | $34.2M | $14.6M | ||
| Q1 25 | $26.9M | $22.4M | ||
| Q4 24 | $111.9M | $14.3M | ||
| Q3 24 | $35.9M | $18.6M | ||
| Q2 24 | $32.1M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 36.2% | ||
| Q3 25 | 38.0% | 10.0% | ||
| Q2 25 | 35.1% | 22.3% | ||
| Q1 25 | 30.4% | 30.4% | ||
| Q4 24 | 32.6% | 23.0% | ||
| Q3 24 | 33.1% | 26.1% | ||
| Q2 24 | 36.6% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | 35.5% | 28.5% | ||
| Q3 25 | 27.1% | 7.9% | ||
| Q2 25 | 28.1% | 17.5% | ||
| Q1 25 | 23.4% | 23.8% | ||
| Q4 24 | 95.2% | 18.2% | ||
| Q3 24 | 30.0% | 20.5% | ||
| Q2 24 | 29.9% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $0.20 | $0.95 | ||
| Q3 25 | $0.15 | $0.27 | ||
| Q2 25 | $0.14 | $0.47 | ||
| Q1 25 | $0.11 | $0.71 | ||
| Q4 24 | $0.45 | $0.45 | ||
| Q3 24 | $0.15 | $0.60 | ||
| Q2 24 | $0.13 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.3B |
| Total Assets | $624.2M | $10.2B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $87.6M | $424.2M | ||
| Q3 25 | $61.4M | $626.9M | ||
| Q2 25 | $90.3M | $334.1M | ||
| Q1 25 | $71.6M | $486.2M | ||
| Q4 24 | $103.1M | $470.2M | ||
| Q3 24 | $86.7M | $321.2M | ||
| Q2 24 | $88.2M | $288.1M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $477.3M | $1.2B | ||
| Q3 25 | $431.2M | $1.2B | ||
| Q2 25 | $398.3M | $1.2B | ||
| Q1 25 | $373.4M | $1.2B | ||
| Q4 24 | $349.0M | $1.1B | ||
| Q3 24 | $231.9M | $1.1B | ||
| Q2 24 | $188.3M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $624.2M | $9.7B | ||
| Q3 25 | $568.7M | $9.8B | ||
| Q2 25 | $558.4M | $9.7B | ||
| Q1 25 | $510.6M | $9.8B | ||
| Q4 24 | $488.7M | $9.7B | ||
| Q3 24 | $390.6M | $10.0B | ||
| Q2 24 | $376.4M | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $158.9M | ||
| Q3 25 | $13.3M | $59.3M | ||
| Q2 25 | $21.1M | $20.6M | ||
| Q1 25 | $-19.7M | $35.6M | ||
| Q4 24 | $50.2M | $108.5M | ||
| Q3 24 | $25.0M | $39.6M | ||
| Q2 24 | $45.6M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $151.1M | ||
| Q3 25 | $-1.1M | $56.8M | ||
| Q2 25 | $18.7M | $19.6M | ||
| Q1 25 | $-24.4M | $34.8M | ||
| Q4 24 | $47.5M | $86.4M | ||
| Q3 24 | $24.0M | $32.2M | ||
| Q2 24 | $43.6M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 146.0% | ||
| Q3 25 | -0.8% | 51.7% | ||
| Q2 25 | 15.3% | 23.5% | ||
| Q1 25 | -21.2% | 37.0% | ||
| Q4 24 | 40.4% | 110.3% | ||
| Q3 24 | 20.0% | 35.5% | ||
| Q2 24 | 40.7% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 7.6% | ||
| Q3 25 | 10.7% | 2.3% | ||
| Q2 25 | 2.0% | 1.2% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 28.1% | ||
| Q3 24 | 0.9% | 8.1% | ||
| Q2 24 | 1.9% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 5.38× | ||
| Q3 25 | 0.36× | 6.88× | ||
| Q2 25 | 0.62× | 1.41× | ||
| Q1 25 | -0.73× | 1.59× | ||
| Q4 24 | 0.45× | 7.60× | ||
| Q3 24 | 0.70× | 2.13× | ||
| Q2 24 | 1.42× | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
